🇺🇸 FDA
Pipeline program

Anagrelide Hydrochloride

SPD422-308

Phase 3 small_molecule completed

Quick answer

Anagrelide Hydrochloride for Essential Thrombocythemia (ET) is a Phase 3 program (small_molecule) at TAKEDA PHARMACEUTICAL CO LTD with 1 ClinicalTrials.gov record(s).

Program details

Company
TAKEDA PHARMACEUTICAL CO LTD
Indication
Essential Thrombocythemia (ET)
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials